NEWARK, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will host an Analyst and Investor Day on Wednesday, March 23, 2016. The details are as follows:
|Date: Wednesday, March 23, 2016|
|Time: 9:00 a.m. EDT – 11:30 a.m. EDT (6:00 a.m. PDT – 8:30 a.m. PDT)|
|Location: New York, New York|
|Depomed management:||Jim Schoeneck, President and Chief Executive Officer|
|August Moretti, Senior Vice President and Chief Financial Officer|
|Srinivas Rao, M.D., Ph.D., Chief Medical Officer|
|Scott Shively, Chief Commercial Officer|
Joining Depomed’s senior management team will be:
Joseph V. Pergolizzi, Jr., M.D., Chief Operating Officer, Naples Anesthesia & Physician Associates and an Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine. Dr. Pergolizzi is a former Adjunct Faculty member of the Department of Anesthesiology and Pain Medicine at Georgetown University School of Medicine and an Associate Professor in the Department of Pharmacology at Temple University School of Medicine. Dr. Pergolizzi is also a steering committee member of the Food and Drug Administration’s Safe Use Initiative and a consultant to the National Institutes of Health.
Dr. Pergolizzi is the author of over 150 peer reviewed articles, abstracts, platform presentations and book chapters in his areas of interest and expertise. He is an internationally recognized expert in clinical research, pain medicine, anesthesia, internal medicine, pharmacology, regulatory affairs and drug discovery.
Space is limited and attendance is by invitation only. Analysts and institutional investors interested in attending should contact Christopher Keenan of Depomed’s Investor Relations department at firstname.lastname@example.org to request an invitation.
The presentations, as well as the question and answer session, will be simultaneously webcast on the Investor Relations page of Depomed’s website at www.depomed.com. A recording of the webcast and slideshow will be archived for 30 days.
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payers we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000